NEWS / Technology
Feline Weight-Loss Drugs Move to Clinical Trials – What It Means for Pet Owners and Investors
<img src="https://healthylife7.com/wp-content/uploads/2026/07/kalbir-talwar-briefs.jpg” alt=””>
Kalbir Talwar
Published Jul 19, 2026
[tts_player]
Share:
Summary:
- According to 2022 veterinary assessments, 61% of cats examined in the U.S. were overweight or obese.
- Two biotech companies are running early-stage trials of GLP-1 drugs designed to treat obesity in overweight cats.
- Results from both trials are expected later this year, but how affordable the drugs will be for owners is still an open question.
Pet Obesity Is a Real Problem
The Association for Pet Obesity Prevention reported that approximately 59% of U.S. dogs brought to vets in 2022 were also overweight or obese
Cats are especially tricky to treat. You cannot walk a cat. And many of them, as any owner knows, have a strong opinion about their food. “He just gobbles down all the food,” said Amy, a Dallas cat owner whose five-year-old cat Felix is overweight
Carrying extra weight doesn’t just affect a cat’s appearance – it can also reduce its lifespan and put pressure on its joints and heart
That frustration is now catching the attention of drug companies. The same class of drugs that turned Novo Nordisk and Eli Lilly into giants for human weight loss – GLP-1s – is being tested for pets
Get the market news that matters in a five-minute read with Market Briefs, our free daily newsletter
A once-weekly GLP-1 treatment for overweight and obese cats is being studied in a Cornell University clinical trial sponsored by Akston Biosciences. About 70 overweight or obese cats will be evaluated over roughly three months. Meanwhile, a San Francisco biotech called OKAVA Pharmaceuticals is testing a long-acting implant that delivers the drug continuously for up to six months. They call it the “MEOW-1” trial
“Feline obesity is one of the most common yet least effectively treated health issues in veterinary medicine,” Todd Zion, CEO of Akston Biosciences, made that statement in November when his firm revealed the trial
The Dollars Behind the Pets
The U.S. pet economy is huge – roughly $200 billion in total. By 2030, that number is expected to hit $240 billion. Pet food alone could reach $65 billion in spending by 2026
A big reason for that growth: cat ownership is increasing about three times faster than dog ownership, according to Nestlé. That same company is leaning hard into “Personalized Health” products for pets – things that target digestive health, aging, and longer life. Nestlé claims its newer nutritional products can extend a cat’s healthy lifespan by more than a year
Morgan Stanley analyst Simeon Gutman describes the shift as “an expansion from premiumization into medicalization, rather than owners abandoning premium food.” In plain English: owners are spending more on keeping pets healthy, not just on fancier kibble
The catch: Gutman also warns that the hype around pet GLP-1s might be overblown. “The most overhyped part is the assumption that pet obesity drugs will replicate the human GLP-1 market in terms of penetration and pricing,” he said
Amy, the cat owner in Dallas, put it plainly: “If they can make one for my cat, that would be great.”
For investors, the lesson is less about betting on one drug and more about watching where the health trend goes. Pet owners are spending more every year on their animals, and the line between human medicine and pet medicine is getting blurrier. That shift could reward a lot of companies – but it will take time, and a few furry test subjects, to know for sure
Join Market Briefs, our free daily newsletter, for a quick daily rundown of the markets
Disclosure
Trending Briefs
Feline Weight-Loss Drugs Move to Clinical Trials – What It Means for Pet Owners and Investors
Jul 19, 2026
U.S. K-Beauty Sales Surge 48%, Trend Picks Up Speed
Jul 19, 2026
Truth Social’s Premium Data Feed Offers Speed to Traders for $100K Monthly
Jul 19, 2026
EV Charging Network Shows Major Reliability Gains After 600-Mile Test
Jul 18, 2026
Over 8,260 Sickened by Cyclospora; Officials Urge Caution with Salad Greens
Jul 18, 2026
Berkshire Chairman Cautions on Speculation and Tech Investment
Jul 18, 2026
Cyclospora Outbreak Sickens 1,644; Tainted Lettuce from Taylor Farms at Taco Bell
Jul 18, 2026
United Airlines Hit by Saturday Morning Tech Failure
Jul 18, 2026
Renovated Queens Home Linked to Trump Lands Buyer After Price Cuts
Jul 18, 2026
Most Market Indicators Show Positive Shift, Earnings Remain Key Hurdle
Jul 18, 2026
Get Market Briefs every morning for free!
No fluff. No noise. No politics. Just finance news in 5 minutes.
Subscribe Free
